Treatment with anti-CXCL12 blood serum decreases proliferation and migration of implanted neural stem cells or neural precursor cells, and impairs remyelination in a murine model of hepatitis virus-induced demyelination; moreover, blocking CXCR4 with the antagonist AMD3100 decreases the differentiation ability of implanted NSCs and NPCs [43]. This evidence concerns the gene CXCL12 and Peripheral demyelination.